Uploaded July 2017 | Updated November 2026, 3 hours ago
During the week of July 17, 2017, Dr. Scott Gottlieb, Commissioner of the Food and Drug Administration, spoke out about the need to curb anti-competitive practices employed by some brand pharmaceutical companies to keep generic competition off the market. By blocking safe, effective and affordable generic alternatives, these brand companies are able to retain their monopolies past the expiration of their patents and artificially preserve their high prices. The Congress is considering two bills to curb these anti-competitive, anti-patient schemes, the FAST Generics Act in the U.S. House of Representatives and the CREATES Act in the United States Senate. The Association for Accessible Medicines urges swift passage of these important bills to provide patients with relief from the high cost of medicine. Learn more at http://www.stopREMSabuse.com.
During the week of July 17, 2017, Dr. Scott Gottlieb, Commissioner of the Food and Drug Administration, spoke out about the need to curb anti-competitive practices employed by some brand pharmaceutical companies to keep generic competition off the market. By blocking safe, effective and affordable generic alternatives, these brand companies are able to retain their monopolies past the expiration of their patents and artificially preserve their high prices. The Congress is considering two bills to curb these anti-competitive, anti-patient schemes, the FAST Generics Act in the U.S. House of Representatives and the CREATES Act in the United States Senate. The Association for Accessible Medicines urges swift passage of these important bills to provide patients with relief from the high cost of medicine. Learn more at http://www.stopREMSabuse.com.










